全文获取类型
收费全文 | 216489篇 |
免费 | 16597篇 |
国内免费 | 5222篇 |
专业分类
耳鼻咽喉 | 2051篇 |
儿科学 | 2950篇 |
妇产科学 | 3184篇 |
基础医学 | 25216篇 |
口腔科学 | 5719篇 |
临床医学 | 17250篇 |
内科学 | 27203篇 |
皮肤病学 | 2417篇 |
神经病学 | 14506篇 |
特种医学 | 15287篇 |
外国民族医学 | 27篇 |
外科学 | 18413篇 |
综合类 | 29106篇 |
现状与发展 | 24篇 |
一般理论 | 8篇 |
预防医学 | 15542篇 |
眼科学 | 5220篇 |
药学 | 26349篇 |
60篇 | |
中国医学 | 12694篇 |
肿瘤学 | 15082篇 |
出版年
2024年 | 206篇 |
2023年 | 3121篇 |
2022年 | 4325篇 |
2021年 | 8884篇 |
2020年 | 7806篇 |
2019年 | 7709篇 |
2018年 | 7608篇 |
2017年 | 8200篇 |
2016年 | 8148篇 |
2015年 | 7773篇 |
2014年 | 9781篇 |
2013年 | 13317篇 |
2012年 | 10949篇 |
2011年 | 12948篇 |
2010年 | 8598篇 |
2009年 | 8759篇 |
2008年 | 10329篇 |
2007年 | 11431篇 |
2006年 | 10710篇 |
2005年 | 9712篇 |
2004年 | 8353篇 |
2003年 | 7410篇 |
2002年 | 5830篇 |
2001年 | 5271篇 |
2000年 | 4436篇 |
1999年 | 3697篇 |
1998年 | 2811篇 |
1997年 | 2942篇 |
1996年 | 2691篇 |
1995年 | 2485篇 |
1994年 | 2403篇 |
1993年 | 2016篇 |
1992年 | 1806篇 |
1991年 | 1716篇 |
1990年 | 1500篇 |
1989年 | 1224篇 |
1988年 | 1180篇 |
1987年 | 1086篇 |
1986年 | 978篇 |
1985年 | 1391篇 |
1984年 | 1147篇 |
1983年 | 848篇 |
1982年 | 907篇 |
1981年 | 752篇 |
1980年 | 680篇 |
1979年 | 551篇 |
1978年 | 344篇 |
1977年 | 312篇 |
1976年 | 274篇 |
1975年 | 195篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献
42.
《Saudi Pharmaceutical Journal》2022,30(4):398-406
IntroductionThe risk of mortality in patients with COVID-19 was found to be significantly higher in patients who experienced thromboembolic events. Thus, several guidelines recommend using prophylactic anticoagulants in all COVID-19 hospitalized patients. However, there is uncertainty about the appropriate dosing regimen and safety of anticoagulation in critically ill patients with COVID-19. Thus, this study aims to compare the effectiveness and safety of standard versus escalated dose pharmacological venous thromboembolism (VTE) prophylaxis in critically ill patients with COVID-19.MethodsA two-center retrospective cohort study including critically ill patients aged ≥ 18-years with confirmed COVID-19 admitted to the intensive care unit (ICU) at two tertiary hospitals in Saudi Arabia from March 1st, 2020, until January 31st, 2021. Patients who received either Enoxaparin 40 mg daily or Unfractionated heparin 5000 Units three times daily were grouped under the “standard dose VTE prophylaxis and patients who received higher than the standard dose but not as treatment dose were grouped under ”escalated VTE prophylaxis dose“. The primary outcome was the occurance of thrombotic events, and the secondary outcomes were bleeding, mortality, and other ICU-related complications.ResultsA total of 758 patients were screened; 565 patients were included in the study. We matched 352 patients using propensity score matching (1:1). In patients who received escalated dose pharmacological VTE prophylaxis, any case of thrombosis and VTE were similar between the two groups (OR 1.22;95 %CI 0.52–2.86; P = 0.64 and OR 0.75; 95% CI 0.16–3.38; P = 0.70 respectively). However, the odds of minor bleeding was higher in patients who received escalated VTE prophylaxis dose (OR 3.39; 95% CI 1.08–10.61; P = 0.04). There was no difference in the 30-day mortality nor in-hospital mortality between the two groups (HR 1.17;95 %CI0.79–1.73; P = 0.43 and HR 1.08;95 %CI 0.76–1.53; P = 0.83, respectively).ConclusionEscalated-dose pharmacological VTE prophylaxis in critically ill patients with COVID-19 was not associated with thrombosis, or mortality benefits but led to an increased risk of minor bleeding. This study supports previous evidence regarding the optimal dosing VTE pharmacological prophylaxis regimen for critically ill patients with COVID-19. 相似文献
43.
- DNA is the sequence that codes for proteins.
- Messenger RNA is transcribed from the DNA sequence of genes and translated into protein.
- It can be difficult to predict how a change in the DNA sequence will affect messenger RNA and protein quantity and quality.
- DNA translocation changes can cause the joining of sequences from two different genes or different parts of the same gene.
- DNA sequencing is often used clinically to predict how DNA changes might affect proteins.
- Alternatively, RNA sequencing can be used as a more direct measure of the effect of DNA changes on the protein products.
- This sequencing is important for identifying changes in cancer that may indicate response to targeted therapy, prognosis, or diagnosis.
44.
Marie V. Plaisime PhD MPH Marie Jipguep-Akhtar PhD Joseph J. Locascio PhD Harolyn M. E. Belcher MD MHS Rachel R. Hardeman PhD MPH Katherine Picho-Kiroga PhD Sylvia P. Perry PhD Sean M. Phelan PhD MPH Michelle van Ryn PhD LMFT MPH John F. Dovidio PhD 《Health services research》2023,58(Z2):229-237
Objective
To examine the experience of interracial anxiety among health professionals and how it may affect the quality of their interactions with patients from racially marginalized populations. We explored the influence of prior interracial exposure—specifically through childhood neighborhoods, college student bodies, and friend groups—on interracial anxiety among medical students and residents. We also examined whether levels of interracial anxiety change from medical school through residency.Data Source
Web-based longitudinal survey data from the Medical Student Cognitive Habits and Growth Evaluation Study.Study Design
We used a retrospective longitudinal design with four observations for each trainee. The study population consisted of non-Black US medical trainees surveyed in their 1st and 4th years of medical school and 2nd and 3rd years of residency. Mixed effects longitudinal models were used to assess predictors of interracial anxiety and assess changes in interracial anxiety scores over time.Principal Findings
In total, 3155 non-Black medical trainees were followed for 7 years. Seventy-eight percent grew up in predominantly White neighborhoods. Living in predominantly White neighborhoods and having less racially diverse friends were associated with higher levels of interracial anxiety among medical trainees. Trainees' interracial anxiety scores did not substantially change over time; interracial anxiety was highest in the 1st year of medical school, lowest in the 4th year, and increased slightly during residency.Conclusions
Neighborhood and friend group composition had independent effects on interracial anxiety, indicating that premedical racial socialization may affect medical trainees' preparedness to interact effectively with diverse patient populations. Additionally, the lack of substantial change in interracial anxiety throughout medical training suggests the importance of providing curricular tools and structure (e.g., instituting interracial cooperative learning activities) to foster the development of healthy interracial relationships. 相似文献45.
《Drug discovery today》2022,27(6):1733-1742
Compounds that exhibit assay interference or undesirable mechanisms of bioactivity are routinely encountered in assays at various stages of drug discovery. We observed that assays for the investigation of thiol-reactive and redox-active compounds have not been collected in a comprehensive review. Here, we review these assays and subject them to experimental optimization to improve their reliability. We demonstrate the usefulness of our assay cascade by assaying a library of bioactive compounds, chemical probes, and a set of approved drugs. These high-throughput assays should complement the array of wet-lab and in silico assays during the initial stages of hit discovery campaigns to pursue only hit compounds with tractable mechanisms of action. 相似文献
46.
Major depressive disorder and other neuropsychiatric disorders are often managed with long-term use of antidepressant medication. Fluoxetine, an SSRI antidepressant, is widely used as a first-line treatment for neuropsychiatric disorders. However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease. Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro. In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease. The goal of this study was to assess the effect of fluoxetine exposure on the prostaglandin biosynthetic pathway and lipid accumulation in a hepatic cell line (H4-II-E-C3 cells). Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ12,14PGJ2 a PPAR gamma ligand. The effects of fluoxetine to induce lipid accumulation were attenuated with a PTGS1 specific inhibitor (SC-560), whereas inhibition of PTGS2 had no effect. Moreover, SC-560 attenuated 15-deoxy-Δ12,14PGJ2 production and expression of PPAR gamma downstream target genes. Taken together these results suggest that fluoxetine-induced lipid abnormalities appear to be mediated via PTGS1 and its downstream product 15d-PGJ2 and suggest a novel therapeutic target to prevent some of the adverse effects of fluoxetine treatment. 相似文献
47.
目的 观察张氏头针治疗儿童多发性抽动症的临床疗效。方法 2019年3月至2020年12月共招募多发性抽动症儿童60例,随机分为头针组和硫必利组,每组各30例。头针组采用毫针针刺双侧运动区、舞蹈震颤控制区及百会、印堂,每周治疗3次,1个月为1个疗程,共治疗4个疗程;硫必利组给予盐酸硫必利片50-100 mg/次,2次/天,1个月为1个疗程,共治疗4个疗程。比较两组患者治疗前后耶鲁综合抽动严重程度量表(Yale global Tic severity scale,YGTSS)、中医证候积分、SF-36健康调查简表(the MOS item short from health survey,SF-36)及临床疗效评价结果。结果 头针组合硫必利组组内比较:二组的YGTSS评分、中医证候积分与治疗前相比具有显著统计学差异(P<0.05),SF-36评分中头针组在生理功能、生理职能、总体健康、情感职能、心理健康等5个维度的评分高于治疗前,差异有统计学意义(P<0.05);硫必利组在生理功能、生理职能、总体健康、心理健康等5个维度的评分高于治疗前,差异有统计学意义(P<0.05);头针组合硫必利组组间比较:头针组治疗后YGTSS评分、中医证候积分均低于硫必利组,差异有统计学意义(P<0.05),头针组在SF-36量表中总体健康和心理健康2个维度照优于硫必利组,差异有统计学意义(P<0.05);治疗结束3个月随访,头针组YGTSS评分、中医证候积分均低于硫必利组,差异有统计学意义(P<0.05)。结论 张氏头针能够很好的改善多发性抽动症的临床症状,提高其生活质量。 相似文献
48.
目的 运用科学知识图谱的手段,分析中医药治疗癫痫的研究进程并提炼重点。方法 设置检索时间为1990年至2020年,检索对象为中国知网(CNKI)该领域的相关文献,运用CiteSpace软件科学、准确地分析这些文献的作者信息、研究(发文)机构、关键词情况。结果 共计纳入文献793篇,马融-张喜莲、刘金民、谢炜、王洪图-张丽萍等领导核心作者团队,北京、广州以及广西中医药大学、天津中医药大学第一附属医院、南方医科大学等单位为主要进行相关研究的机构,高频关键词包括大鼠、难治性癫痫、小儿癫痫、海马、脑电图等,作用机制、网络药理学、肠道菌群、氧化应激、分子生物学等为近年来的热点与前沿。结论 通过借用知识图谱的分析能帮助提炼国内中医药治疗癫痫研究领域的重点,全面分析并科学判断近年来该领域的热点及前沿,为未来的研究夯实基础并把握方向。 相似文献
49.
甲状腺癌是内分泌系统常见的恶性肿瘤之一,其发病率呈逐年上升趋势。甲状腺癌以分化型甲状腺癌(differentiated thyroid carcinoma, DTC)为主,尽管多数DTC患者经规范化治疗后预后良好,但由于部分肿瘤的病理类型侵袭性较高或肿瘤组织分化程度较低,病情进展迅速导致患者总生存时间显著缩短。近年来,有关炎症与肿瘤之间相关性的研究越来越多,炎性微环境的改变在肿瘤发病机制中的作用逐渐被证实,更多的证据表明细胞因子可作为肿瘤的良恶性鉴别、预后判断提示及诊疗方案选择等的重要参考依据。本文就部分细胞因子在DTC诊疗中的应用进展进行论述,旨在为DTC的诊疗与预后判断等提供参考依据。 相似文献
50.
《Cirugía espa?ola》2023,101(2):116-122
IntroductionMetastasis is remaining one of the major problems in cancer treatment. Like many other malignancies, urogenital tumors originating from kidney, prostate, testes, and bladder tend to metastasize to the lungs.The aim of this retrospective study is to evaluate the operative results and prognosis of pulmonary metastasectomy in patients with primary urogenital tumors.MethodsThis study was approved by the local ethical committee. We retrospectively analyzed the surgical and oncological results of patients who underwent lung resections for urogenital cancer metastases in our department between 2002 and 2018. Demographic data and clinicopathological features were extracted from the medical records. Survival outcomes according to cancer subtypes and early postoperative results of VATS and thoracotomy were analyzed.Results22 out of 126 patients referred for pulmonary metastasectomy to our department had metastases from urogenital tumors. These patients consisted of 17 males and five females. Their metastasis originated from renal cell carcinoma (RCC; n = 9), bladder tumor (n = 7), testis tumors (n = 4), and prostate cancer (n = 2). There was no intraoperative complication. Postoperative complications were seen in 2 patients.ConclusionsAlthough pulmonary metastasectomy in various types of tumors is well known and documented, the data is limited for metastases of urogenital cancers in the literature. Despite the limitations of this study, we aim to document our promising results of pulmonary metastasectomy in patients with primary urogenital tumors and wanted to emphasize the role of minimally invasive approaches. 相似文献